Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity ...

Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...

University of New Mexico researchers found that the immune enzyme OTULIN drives tau production, brain inflammation and aging.

Scientists are testing CRISPR gene editing as a potential HIV cure after successfully removing the virus from infected cells ...

Acuitas Therapeutics, a leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, announced that it ...

Machine learning models reveal that histone marks are predictive of gene expression across human cell types and highlight important nuances between natural control and the effects of CRISPR-Cas9-based ...

Jan 12 () - Novartis will continue to do bolt-on deals and its capital allocation priorities remain unchanged, CEO Vasant ...

“What a career Leonardo DiCaprio has had,” began Glaser. “Countless iconic performances, you've worked with every great ...

"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are ...

Ionis Pharmaceuticals, Inc. today announced highlights from the Company's 2025 achievements and provided additional updates on key milestones expected in 2026. Ionis will provide a business update at ...

Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer ...